Objective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease typically associated with elevated serum immunoglobulin G (IgG). Hypogammaglobulinemia in SLE patients has been attributed to immunosuppressive treatment or a transient effect associated with nephrotic syndrome. We retrospectively reviewed pediatric SLE patients from a single institution to identify patients with hypogammaglobulinemia and risk factors for hypogammaglobulinemia. Methods: A total of 116 pediatric SLE cases from 1997 to 2011 were reviewed and patients with hypogammaglobulinemia (IgG < 500 mg/dl) were identified. The two cohorts were evaluated for association with age, sex, presence of lupus nephritis at SLE diagnosis, disease activity at diagnosis, initial IgG level, and drug treatment. Results: Eighty-six patients were included in our study, with a median age of 15 years and a median follow-up of 39.5 months. Seven percent (six of 86) of patients had hypogammaglobulinemia with a median onset of 27 months (0-72 months) after SLE diagnosis. Significant associations were noted for white race (p value 0.029), male sex (p value 0.009), and the presence of lupus nephritis at SLE diagnosis (p value 0.004). Use of immunosuppressive treatment did not show a statistical association with hypogammaglobulinemia, although two of the patients with hypogammaglobulinemia did receive rituximab. Most patients with hypogammaglobulinemia received intravenous immunoglobulin (IVIG) replacement therapy because of infections and/ or concern for infection. Conclusion: Measurement of immunoglobulin levels during treatment in SLE could help identify patients with hypogammaglobulinemia who might require more aggressive follow-up to monitor for increased risk of infection and need for IVIG treatment. A prospective study is needed to validate associated risk factors identified in this study. Lupus (2013) 22, 1382-1387.
Introduction
Systemic lupus erythematosus (SLE) is characterized by immune cell activation, including T and B cells, with elevated serum immunoglobulin G (IgG) and prominent circulating immune complexes in multiple organs, including the skin, heart, lungs, kidneys, and joints. 1 SLE predominantly affects women of reproductive age, with a female:male prevalence ratio of 9 : 1, and approximately 15%-20% of SLE patients are diagnosed prior to 16 years of age. [1] [2] [3] [4] [5] Studies using standardized disease measures comparing cohorts of adult and pediatric patients with SLE suggest that children have more active disease at diagnosis and acquire more permanent organ damage compared to adults. 2, 4 Patients with SLE frequently have polyclonal immune activation with elevated total IgG and specific antibodies directed against nuclear antigens, including anti-double-stranded DNA (anti-dsDNA) and anti-Sm antibodies. 6 While rare, hypogammaglobulinemia has been described in SLE. 6, 7 Patients with SLE and other autoimmune diseases typically receive immunosuppressive medications, and it is challenging to balance appropriate treatment while minimizing the risk of opportunistic and serious infections. 8 The goal of this study is to review pediatric SLE patients from our institution to delineate the frequency of, and risk factors for, hypogammaglobulinemia with SLE. We compared clinical and laboratory findings of pediatric SLE patients with and without hypogammaglobulinemia. We did not find a significant association between hypogammaglobulinemia and medication usage or disease activity; however, we did discover associations with male sex, white race, and the presence of lupus nephritis at diagnosis of SLE.
Methods
We retrospectively reviewed records of patients with a diagnosis of SLE (International Classification of Diseases (ICD)-9 code 710.0) seen in our Pediatric Rheumatology clinic at Washington University from 1997 to 2011. All patients fulfilled at least four of the 1997 American College of Rheumatology (ACR) classification criteria for SLE. 9 To evaluate for hypogammaglobulinemia, inclusion criteria included having an evaluable IgG level within three months of diagnosis and two or more IgG levels during follow-up. Patients with insufficient data for Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scoring at diagnosis or presence of known immunodeficiency states were excluded. Clinical and laboratory characteristics including a disease activity score (SLEDAI) were determined at the time of SLE diagnosis for all patients. We determined whether SLE patients ever had hypogammaglobulinemia, defined as an IgG level of <500 mg/dl (two standard deviations below mean for age 4 years to adulthood). 10, 11 For patients with hypogammaglobulinemia, their clinical course and SLEDAI scores were also determined at the time of detection of low IgG. Charts of patients with hypogammaglobulinemia were also further reviewed for symptoms related to infection, immunoglobulin levels, and vaccine response. Comparisons of categorical variables were made using Chi-square or Fisher's exact tests as appropriate. Comparisons of continuous and ordinal variables were made using the Wilcoxon-Mann-Whitney test because of the non-normal distribution of these variables. Tests were two tailed and p < 0.05 was considered significant. All statistical analyses were performed using SAS 9.2 (SAS Institute Inc, Cary, NC, USA). This research was conducted in accordance with the guidelines for research studies from the Human Resources Research Protection Office at Washington University.
Results

Patient characteristics
A total of 116 SLE patients were treated in our Pediatric Rheumatology clinic from 1997 to 2011. A total of 86 patients fulfilled our inclusion and exclusion criteria with a median age of 15 years and a mean follow-up of 39.5 months. Half of the patients were African Americans (43/86), most were females (78/86, 91%), and 42% (36/86) had lupus nephritis at diagnosis of SLE (Tables 1 and 2 ). There were six pediatric patients with SLE who had hypogammaglobulinemia (Table 1 ). There was no difference in the age or SLEDAI scores of the two cohorts at presentation. The mean IgG level for all patients at diagnosis was 1812 mg/dl (range of 170-5860 mg/dl), consistent with prior observations that most SLE patients have hypergammaglobulinemia. 12, 13 Factors associated with hypogammaglobulinemia
To determine whether medications affected patients' IgG level, we compared medication usage in the two groups ( Table 1 ). All patients received prednisone at some point during their clinical course. There was no statistically significant difference in the use of cyclophosphamide (CYC), rituximab, or mycophenolate mofetil (MMF) between the two groups (Table 1) . Two patients with hypogammaglobulinemia received B-cell depleting therapy with rituximab prior to development of hypogammaglobulinemia (indicated in Table 3 ); 12.5% of patients without hypogammaglobulinemia also received rituximab, which while lower, was not statistically different (Table 1) . There was a significant association with hypogammaglobulinemia and male sex (p ¼ 0.009), lupus nephritis at diagnosis of SLE (p ¼ 0.004), and white race (p ¼ 0.029) (Tables 1  and 2) . Indeed, all patients with hypogammaglobulinemia had nephritis at SLE diagnosis. Interestingly, while males comprised a minority of patients with SLE (9.3%, eight of 86), 50% (three of six) of SLE patients with hypogammaglobulinemia were white males, and 37.5% (three of eight) of all male patients had hypogammaglobulinemia.
Lupus nephritis and hypogammaglobulinemia
We then evaluated the course of patients with hypogammaglobulinemia, with particular attention to lupus nephritis. All six patients with hypogammaglobulinemia had kidney involvement at presentation ( Table 4 ). The onset of decreased IgG ranged from 0 to 72 months after diagnosis of SLE and lupus nephritis, with a median onset of 27 months. Two patients had IgG levels less than 500 mg/dl within three months of SLE diagnosis, suggesting that their hypogammaglobulinemia preceded or coincided with the onset of SLE. Hypogammaglobulinemia patients had different types of lupus nephritis (Table 4) , including type II, II/III, IV, and V (based on World Health Organization (WHO) 1982 Lupus Nephritis Classification). At the time of diagnosis of hypogammaglobulinemia, most patients had dsDNA antibodies, indicative of active disease. 14 Serum complements (C3 and/or C4) were low in four of six patients at the time of low IgG. All of the patients had elevated urine protein:creatinine ratio (>0.2) at the time hypogammaglobulinemia was first observed, suggestive of urinary protein loss as a potential mechanism of hypogammaglobulinemia. However, only three of six patients had nephrotic-range proteinuria (ratio > 3.5), and only 
Treatment and course of patients with hypogammaglobulinemia
Most patients (four of six) with hypogammaglobulinemia received intravenous immunoglobulin (IVIG) replacement therapy, 400 mg/kg every four weeks ( Table 5 ). The decision to treat with IVIG was based on immunoglobulin levels, infection history, and/or response to vaccination, in addition to infection risk due to immunosuppressive therapy for their SLE (Table 5 ). Antibody responses to vaccination, including Tetanus, Haemophilus influenza type B (Hib), and/or S. pneumoniae, were measured in five patients prior to initiation of IVIG ( Table 5 ). The patients who did not receive IVIG (Patients 1 and 5) did not have infections and had improvement of IgG levels to >500 mg/dl after two to five months of immunosuppressive treatment for their SLE. Patient 2 had recurrent sinusitis and poor response to boosting with a nonconjugated S. pneumonia vaccine. He was started on IVIG therapy, and has continued to receive subcutaneous immunoglobulin replacement 16 months after detection of hypogammaglobulinemia. Patient 3 had recurrent infections with low IgM and IgA levels and nonprotective titers to S. pneumoniae and Hib. She received two courses of rituximab that may have contributed to her hypogammaglobulinemia. She has continued on IgG replacement for >30 months. Patient 4 also had a history of rituximab treatment and started IVIG because of persistence of clinical pneumonia that did not improve with IV antibiotics. Patient 6 was started on IVIG for very low IgG (65 mg/dl) and concern for an increased risk of infection. Patients 4 and 6 had normalization of their IgG and were able to stop IVIG after two months (Patient 4) and four months (Patient 6).
Discussion
Herein, we describe risk factors for development of hypogammaglobulinemia in our cohort of pediatric SLE patients. While infrequent, we observed hypogammaglobulinemia in 6.9% (six of 86) of pediatric patients. Strikingly, 50% of patients with hypogammaglobulinemia were white males, even though males constituted only 9.3% (eight of 86) of all patients. In addition to male sex and white race, the presence of nephritis at SLE diagnosis also correlated with hypogammaglobulinemia. However, there was no statistically significant correlation between medication usage, including rituximab, and hypogammaglobulinemia, suggesting that prospective investigation of this in a larger study is warranted.
Various forms of antibody deficiencies, both congenital and acquired, have been described in patients with SLE, including: 1) selective IgA deficiency, 2) common variable immunodeficiency (CVID), 3) drug-induced hypogammaglobulinemia, 4) selective IgM deficiency, and 5) hypogammaglobulinemia secondary to nephrotic syndrome. 6, 15 Selective IgA deficiency is the most common antibody deficiency reported in SLE, and is also the most common primary immunodeficiency disorder in the general population, with an incidence of approximately one in 600 in western countries. 16 Previous studies have suggested a possible link between selective IgA deficiency and autoimmunity. 17 Interestingly, the frequency of IgA deficiency in SLE patients has been reported as higher than the general population, and was seen in approximately 2%-5% of adult and 5% of pediatric SLE patients. 15, 18, 19 Patients with SLE and IgA deficiency do not appear to have more severe disease than SLE patients with normal IgA levels. 18, 19 In the current study, half of patients who developed hypogammaglobulinemia had concomitantly decreased IgA levels. In two of these patients (Patients 1 and 6 While all patients continued to have significant lupus activity, they did not find a correlation with presence of low IgG levels and the amount of protein excreted in the urine. 20 All of the patients with hypogammaglobulinemia presented here had lupus nephritis at presentation (Class II-V), and there was a significant correlation between lupus nephritis at diagnosis and development of hypogammaglobulinemia. However, only two patients had nephrotic-range proteinuria with decreased albumin, suggesting that similar to the findings by Cronin et al., urinary losses might not account for hypogammaglobulinemia in all patients.
Immunosuppressive treatment, such as B-cell depleting therapy with rituximab, has been reported to cause prolonged (>6 months) hypogammaglobulinemia in children with autoimmune hemolytic anemia. 21 CYC use in adults with antineutrophil cytoplasmic antibodies (ANCA)associated vasculitis caused a decrease in IgG values (median value of 12.8 g/l to 9.17 g/l), at 14.5 and 30 months. 22 Further IgG decline (7.11 g/l) was observed in patients who received rituximab after having previously received CYC. 22 Two of the six patients with hypogammaglobulinemia presented here received rituximab, and both initially had elevated IgG (4080 and 1600 mg/dl), suggesting that rituximab may have played a role in their hypogammaglobulinemia. One of these patients has required >30 months of IVIG replacement (Patient 3), while the second had transient hypogammaglobulinemia, which would be more consistent with rituximab, and required only a short (two months) course of IVIG.
The diagnosis and treatment of an autoimmune disease with an underlying immune deficiency can be challenging, and there is overlap in these disease processes. For example, SLE and CVID both involve dysregulation of T and B cells, and patients with CVID frequently have autoimmune manifestations. 6, 7 However, while hypergammaglobulinemia is a frequent finding in SLE, CVID is characterized by failure of antibody response. 12, 13, 23 Factors that have been attributed as common etiologies in both diseases include disturbed T and B cell homeostasis and selection, altered antigen receptor signaling, increased B-cell activating factor (BAFF) levels, and possibly altered Toll-like receptor (TLR) signaling. 24 Among our six patients with hypogammaglobulinemia, only one (Patient 3) met criteria for CVID with persistently low IgG, IgA, and IgM, recurrent infections, and poor vaccine response. However, she had no evidence of immune deficiency at presentation (IgG 4080 g/dl). She developed hypogammaglobulinemia 72 months after her SLE diagnosis and treatment. Her CVID-phenotype was perhaps caused by prolonged immunosuppressive treatment for SLE, including rituximab and cyclophosphamide. While other patients did not meet criteria for CVID, most (four of six) did require IVIG replacement therapy at some point in their treatment because of either infection or low IgG. However, only two patients required IVIG long term (>12 months) because of infection, persistently low IgG, and poor response to vaccination.
To our knowledge, this is the first study that explores the prevalence of and risk factors for hypogammaglobulinemia in pediatric SLE. Our findings suggest that while a minority of patients develop hypogammaglobulinemia, there may be identifiable risk factors, including male sex, white race, and lupus nephritis at onset, and some patients may require IVIG replacement. Intriguingly, a high percentage of pediatric SLE patients with hypogammaglobulinemia were white males, a population not typically associated with SLE. It is interesting to speculate an underlying immune defect that makes them susceptible to immune dysregulation, as they do not have traditional risk factors for SLE. We also found that half of the patients with hypogammaglobulinemia had persistent IgA deficiency, and it will be interesting to determine if this is an independent risk factor. Lupus nephritis at diagnosis was associated with an increased risk of hypogammaglobulinemia, possibly related to urinary protein loss or a marker of more severe disease. Finally, we did not find a statistical significance in the role of immunosuppressive treatment, although the absolute number of patients with hypogammaglobulinemia was small and this will require further investigation. Our study suggests the need for prospective studies evaluating risk factors identified here. In summary, our findings document hypogammaglobulinemia requiring intervention in a small but significant percentage ($7%) of pediatric SLE patients. Serial monitoring of immunoglobulin levels at diagnosis and during therapy may be helpful in early identification of patients with hypogammaglobulinemia who are at risk for potentially serious infections.
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